The FDA wants to pull its approval of a drug. It’s not so easy.

The FDA's attempt to withdraw Tavneos signals that drugs approved on potentially compromised data may be removed from the US market, affecting patient access and treatment options.

The U.S. Food and Drug Administration (FDA) is proposing to withdraw approval for the drug Tavneos, marketed by Amgen, citing manipulated study data and reports of serious liver injury. Tavneos, used to treat a rare autoimmune form of vasculitis, was approved in October 2021 based on a study by ChemoCentryx, which was later acquired by Amgen for nearly $4 billion. An investor lawsuit uncovered evidence suggesting ChemoCentryx employees manipulated the pivotal trial data. The FDA stated the drug now lacks "substantial evidence" of efficacy. In response, the New England Journal of Medicine retracted the trial paper, the European Union removed Tavneos from the market, and the UK announced similar plans. Amgen disputes the FDA's claims, asserting the drug remains effective and should stay available. A court hearing is scheduled for October 29 regarding a proposed $69 million settlement for the investor lawsuit.

The FDA's challenge to Tavneos' approval highlights a critical regulatory vulnerability: the potential for manipulated data in pivotal trials, especially when conducted by smaller biotechs acquired by larger pharmaceutical companies. This situation raises concerns about the integrity of the approval process and the assurances patients and physicians have regarding drug efficacy and safety. The agency's struggle to swiftly revoke approval underscores the complexities of de-listing drugs, even when significant data integrity issues emerge, creating a protracted period of uncertainty for all stakeholders.

This case suggests that regulatory bodies may face increased pressure to re-evaluate approvals if post-market scrutiny uncovers substantial evidence of data manipulation or unexpected severe side effects. The financial implications for Amgen, which invested heavily in ChemoCentryx and Tavneos, are substantial, as are the potential consequences for patients who rely on the drug and the broader pharmaceutical industry's reputation. Future drug development and approval pathways may need to incorporate more robust mechanisms for continuous data verification and independent post-market surveillance to prevent similar scenarios.